Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
Novo's high-dose Rybelsus win tees up regulatory filings
BioNTech's COVID-19 vaccine revenue forecasts lower than expected
BrainStorm secures FDA adcomm for ALS therapy NurOwn
*please scroll down for all the latest news*
